Legal & General Group’s Virax Biolabs VRAX Stock Holding History

Legal & General Group’s Portfolio VRAX Stock Details VRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-399	Closed	-$68.4K	–	3522
2023 Q1	$68.4K	Sell	399 -11	-3%	-$2.14K	﹤0.01%	2830
2022 Q4	$73.5K	Buy	+410	New	+$146K	﹤0.01%	2877

Other funds holding VRAX

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Legal & General Group's VRAX Position: Q2 2023 in Review

Legal & General Group sold out of Virax Biolabs (VRAX) in Q2 2023, closing a stake of 399 shares — an estimated $68.4K sold.

Legal & General Group first reported a position in VRAX in Q4 2022 and held it in 2 quarters. The position peaked at $73.5K in Q4 2022. 4 funds tracked by Wall St. Rank hold VRAX as of Q2 2023.

Legal & General Group reported no remaining Virax Biolabs position as of Q2 2023 after selling out during the quarter.
Legal & General Group sold 399 Virax Biolabs shares in Q2 2023, an estimated $68.4K.
Legal & General Group first reported a position in Virax Biolabs in Q4 2022 and held it in 2 quarters.
Legal & General Group's Virax Biolabs position peaked at $73.5K in Q4 2022.
4 funds tracked by Wall St. Rank held Virax Biolabs as of Q2 2023.

Based on Legal & General Group's 13F filing for Q2 2023, filed 14 Aug 2023.